Cell viability assays are essential analytical tools used to assess the physiological health, metabolic activity, and membrane integrity of cells in response to extracellular stimuli, chemical compounds, or environmental changes. These assays play a critical role in pharmaceutical research, enabling quantitative evaluation of compound cytotoxicity, determination of optimal cell culture conditions, and mechanistic investigation of cell stress responses. In drug discovery, viability data inform candidate selection, dose-response characterization, and therapeutic index estimation by comparing effects on diseased versus normal cell populations.
The distinction between cell viability assays (measuring the proportion of living, metabolically active cells) and cytotoxicity assays (measuring cell death or membrane compromise) is often contextual rather than absolute. Many assay platforms provide information relevant to both endpoints, and the choice of method depends on the cellular parameter being measured, the required throughput, the detection modality, and the specific research question.
At Profacgen, we provide comprehensive Cell Viability Assay Services encompassing a broad spectrum of detection principles and platform formats. Our experienced team assists clients in selecting and optimizing the most appropriate viability method for their specific cell model, compound class, and study objectives.
Cell viability can be assessed through multiple cellular parameters, each reflecting a different aspect of physiological status. Profacgen offers assays based on the following core principles:
Profacgen provides a comprehensive panel of viability assays organized by detection principle. The following table summarizes the major methods, their mechanisms, and typical applications.
| Detection Principle | Assay Method | Mechanism | Readout |
|---|---|---|---|
| Membrane integrity | Trypan blue exclusion | Dead cells with compromised membranes take up the dye; viable cells exclude it | Manual or automated counting; percentage viable cells |
| Membrane integrity | Amine-reactive viability dyes | Impermeant dyes bind weakly to surface amines of live cells and strongly to intracellular amines of dead cells | Flow cytometry or fluorescence microscopy; fluorescence intensity |
| Metabolic reduction | MTT, XTT, MTS, WST-1, WST-8 | Viable cells reduce tetrazolium salts to colored formazan products via mitochondrial and cellular dehydrogenases | Colorimetric absorbance (plate reader) |
| Metabolic reduction | Resazurin (AlamarBlue) | Viable cells reduce resazurin to fluorescent resorufin | Fluorometric or colorimetric (plate reader) |
| ATP content | ATP bioluminescence | Luciferase catalyzes ATP-dependent oxidation of luciferin, producing light proportional to ATP concentration | Luminescence (plate reader); highly sensitive |
| Enzymatic activity | Live-cell protease substrates | Cell-permeant fluorogenic substrates are cleaved by constitutive proteases in viable cells | Fluorometric (plate reader) |
| Proliferation | BrdU/EdU incorporation | Nucleoside analogs incorporated during DNA synthesis are detected by antibody or click chemistry | Flow cytometry, microscopy, or plate reader |
| Long-term viability | Colony formation (clonogenic) | Individual viable cells proliferate to form colonies over 7–14 days | Manual colony counting; plating efficiency |
Trypan blue is a negatively charged azo dye that cannot penetrate intact plasma membranes of viable cells. In dead or membrane-compromised cells, the dye enters and stains the cytoplasm blue. This method is straightforward, inexpensive, and requires minimal equipment, making it suitable for routine cell culture monitoring and rapid viability estimates. Profacgen offers both manual hemocytometer counting and automated imaging-based counting for improved throughput and reproducibility.
Figure 1. Determination of cell viability with trypan blue assay. (Kamiloglu et al., 2020)
Amine-reactive viability dyes (such as Live/Dead fixable stains) covalently bind to free amines. In viable cells with intact membranes, these dyes access only surface-exposed amines and produce weak fluorescence. In dead cells, the dyes penetrate the membrane and bind to abundant intracellular amines, generating intense fluorescence. These dyes are compatible with fixation and permeabilization protocols, enabling subsequent immunophenotyping or intracellular staining in the same sample.
Figure 2. Determination of cell viability with fluorescent amine-reactive dyes. (Perfetto et al., 2006)
Tetrazolium salts are reduced by mitochondrial succinate dehydrogenase and other cellular dehydrogenases in metabolically active cells, producing colored formazan products. The intensity of the colored product correlates with the number of viable cells.
Figure 3. Tetrazolium salts assays. (Khalef et al., 2024)
Resazurin is a blue, weakly fluorescent dye that is reduced by viable cells to pink, highly fluorescent resorufin. This assay offers several advantages: it is water-soluble (no solubilization step), minimally toxic (enabling kinetic monitoring of the same cells over time), and compatible with standard fluorescence or absorbance plate readers. The assay is particularly useful for high-throughput screening and longitudinal viability monitoring.
Figure 4. Resazurin reduction assay. (Khalef et al., 2024)
Adenosine triphosphate (ATP) is present in all metabolically active cells and degrades rapidly upon cell death. ATP bioluminescence assays exploit the luciferase-catalyzed oxidation of luciferin, which requires ATP as a cofactor and produces light in direct proportion to ATP concentration. This method offers exceptional sensitivity—capable of detecting fewer than 10 viable cells per well—and is widely used for high-throughput cytotoxicity screening, antimicrobial susceptibility testing, and ATP content normalization in cell-based assays.
Figure 5. Schematic illustration of the principles of ATP assay. (Kamiloglu et al., 2020)
Profacgen provides ATP assays in both endpoint and kinetic formats, with options for lysis-reagent compatibility with downstream applications such as protein quantification or nucleic acid analysis.
Constitutive proteases present in viable cells cleave cell-permeant fluorogenic substrates to release fluorescent products. Upon cell death, protease activity is lost. This method offers good sensitivity, low background, and compatibility with multiplexing (simultaneous measurement of cytotoxicity using a membrane-impermeant protease substrate released from dead cells).
The clonogenic assay measures long-term reproductive viability by plating cells at low density and allowing individual viable cells to proliferate into colonies over 7–14 days. This method is considered the gold standard for assessing the cytotoxic effects of radiation and chemotherapeutic agents because it captures both immediate cell death and delayed reproductive failure. Profacgen offers clonogenic assays with automated colony counting and plating efficiency calculations.
Figure 6. Clonogenic assay. (Khalef et al., 2024)
Choosing the optimal viability assay requires consideration of multiple factors. The following guidance summarizes key selection criteria:
| Consideration | Recommended Approach |
|---|---|
| High-throughput screening | Resazurin, ATP bioluminescence, or water-soluble tetrazolium |
| High sensitivity | ATP bioluminescence or live-cell protease assays |
| Kinetic monitoring | Resazurin or real-time impedance (xCELLigence) |
| Long-term reproductive viability | Clonogenic assay |
| Multiplexing with apoptosis | ATP or resazurin combined with caspase activity or Annexin V staining |
| Primary cells or sensitive cultures | Low-toxicity methods: resazurin or live-cell protease assays |
| Mechanism-of-action studies | Combination of metabolic, membrane integrity, and proliferation endpoints |
Profacgen follows a structured workflow to ensure that viability assays are executed with scientific rigor and produce reliable, interpretable data:
Challenge:
An oncology drug discovery team required rapid cytotoxicity profiling of 2,400 kinase inhibitor compounds across a panel of 12 solid tumor cell lines to identify selective anti-cancer agents with minimal toxicity to normal fibroblasts. The screen needed to deliver quantitative viability data with sufficient dynamic range to distinguish weakly active from highly potent compounds, while maintaining throughput of 100 plates per week.
Solution:
Profacgen implemented a resazurin-based viability assay in 384-well format with automated liquid handling and plate reader detection. Each plate included vehicle controls, positive controls (staurosporine), and cell-free blanks. Cells were treated with compounds at 10-point dose-response concentrations (1 nM to 10 µM) for 72 hours. Viability was measured by resazurin reduction at 4 hours post-addition, with absorbance read at 570 nm and reference correction at 600 nm.
Outcome:
The screen identified 87 compounds with sub-micromolar IC50 values in at least one tumor cell line. Selectivity analysis revealed 23 compounds with >10-fold selectivity for tumor cells versus normal fibroblasts. Dose-response curves were generated for all hits, and 12 compounds were prioritized for mechanism-of-action follow-up. The resazurin format provided robust Z′ factors (>0.7) across all plates, confirming assay reliability at scale. The entire screening campaign was completed in 6 weeks.
Challenge:
An antibody-drug conjugate (ADC) developer needed to characterize the cytotoxicity profile of their novel tubulin-inhibitor payload across target-positive tumor cells, target-negative tumor cells, and normal human cell models. The goal was to demonstrate that cytotoxicity was target-mediated (via ADC internalization) rather than due to nonspecific payload release, thereby supporting the therapeutic index of the ADC format.
Solution:
Profacgen designed a multi-assay cytotoxicity panel employing ATP bioluminescence for high-sensitivity viability measurement, resazurin reduction for metabolic activity assessment, and a live/dead imaging assay for morphological confirmation. The panel included target-positive breast cancer cells (SK-BR-3), target-negative lung cancer cells (A549), normal human dermal fibroblasts, and hepatocytes. Cells were treated with the ADC, a non-targeting isotype control ADC, and free payload for 96 hours.
Outcome:
The ADC induced potent cytotoxicity in target-positive cells (IC50 = 0.3 nM by ATP assay) but showed no significant viability reduction in target-negative cells or normal fibroblasts at concentrations up to 100 nM. The free payload was cytotoxic across all cell types (IC50 = 2–5 nM), confirming that ADC conjugation conferred the desired selectivity. ATP and resazurin assays showed excellent correlation (R2 = 0.94), while live/dead imaging confirmed apoptotic morphology in target-positive cells. The data package supported the ADC's mechanism of action and informed dose selection for in vivo efficacy studies.
Request a Project Consultation
References:
Fill out this form and one of our experts will respond to you within one business day.